Adjuvant Treatment in Premenopausal Breast Cancer

NCT06807749 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-03-24

No results posted yet for this study

Summary

Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Sponsors & Collaborators

  • Clinical Research Technology S.r.l.

    collaborator INDUSTRY
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • Antonella Palazzo · Fondazione Policlinico Gemelli, IRCCS

  • Alessandra Fabi · Fondazione Policlinico Gemelli, IRCCS

Eligibility

Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2026-09-30
Completion
2027-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06807749 on ClinicalTrials.gov